1056934-87-2 Usage
General Description
TERT-BUTYL 4-CHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE is a chemical compound with potential pharmaceutical applications. It is a carboxylate ester derivative of dihydropyrido[4,3-d]pyrimidine, which is a heterocyclic compound. TERT-BUTYL 4-CHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE has a tert-butyl group, a chlorine atom, and a carboxylate group attached to the dihydropyrimidine ring structure. The specific pharmaceutical uses and properties of this compound are not provided, but it likely functions as a potential drug candidate or precursor for further organic synthesis in medicinal chemistry. More detailed information and research would be needed to fully understand the potential applications of TERT-BUTYL 4-CHLORO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDINE-6(5H)-CARBOXYLATE.
Check Digit Verification of cas no
The CAS Registry Mumber 1056934-87-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,6,9,3 and 4 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1056934-87:
(9*1)+(8*0)+(7*5)+(6*6)+(5*9)+(4*3)+(3*4)+(2*8)+(1*7)=172
172 % 10 = 2
So 1056934-87-2 is a valid CAS Registry Number.
1056934-87-2Relevant articles and documents
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration
Meredith, Erik L.,Mainolfi, Nello,Poor, Stephen,Qiu, Yubin,Miranda, Karl,Powers, James,Liu, Donglei,Ma, Fupeng,Solovay, Catherine,Rao, Chang,Johnson, Leland,Ji, Nan,Artman, Gerald,Hardegger, Leo,Hanks, Shawn,Shen, Siyuan,Woolfenden, Amber,Fassbender, Elizabeth,Sivak, Jeremy M.,Zhang, Yiqin,Long, Debby,Cepeda, Rosemarie,Liu, Fang,Hosagrahara, Vinayak P.,Lee, Wendy,Tarsa, Peter,Anderson, Karen,Elliott, Jason,Jaffee, Bruce
, p. 9273 - 9285 (2015/12/23)
The benefit of intravitreal anti-VEGF therapy in treating wet age-related macular degeneration (AMD) is well established. Identification of VEGFR-2 inhibitors with optimal ADME properties for an ocular indication provides opportunities for dosing routes beyond intravitreal injection. We employed a high-throughput in vivo screening strategy with rodent models of choroidal neovascularization and iterative compound design to identify VEGFR-2 inhibitors with potential to benefit wet AMD patients. These compounds demonstrate preferential ocular tissue distribution and efficacy after oral administration while minimizing systemic exposure.
